Gonadorelin Evidence Guide
Gonadorelin has a well-established physiological and clinical evidence base, but its US approval is historical: Factrel and Lutrepulse are discontinued products. It remains a useful GnRH reference compound, while current availability and approved alternatives depend on jurisdiction and indication.
Our Take
Gonadorelin has a well-established physiological and clinical evidence base, but its US approval is historical: Factrel and Lutrepulse are discontinued products. It remains a useful GnRH reference compound, while current availability and approved alternatives depend on jurisdiction and indication.
- Evidence context
- HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Reported research reference: 100mcg IV or subcutaneous (diagnostic bolus); pulsatile 5-20mcg every 60-120 min via pump (therapeutic)
Benefits and Evidence
- Pituitary Function Assessment: Level A, includes human evidence - The GnRH stimulation test using gonadorelin is a standard diagnostic tool for evaluating pituitary gonadotrope reserve and differentiating hypothalamic from pituitary causes of hypogonadism.
- Fertility Restoration: Level A, includes human evidence - Pulsatile gonadorelin therapy effectively restores ovulation in women with hypothalamic amenorrhea and spermatogenesis in men with hypogonadotropic hypogonadism. Pregnancy rates comparable to gonadotropin therapy.
- LH/FSH Stimulation: Level A, includes human evidence - Robust, reproducible stimulation of LH and FSH release demonstrated across numerous clinical studies. LH response is typically greater than FSH response.
Side Effects and Warnings
- Injection site reactions
- Headache
- Nausea
- Flushing
- Ovarian hyperstimulation syndrome (with pulsatile therapy in women)
- Multiple pregnancy risk
- Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy
- Not for use in patients with pituitary tumors
Research Dosage References
- <strong>Intravenous (diagnostic)</strong> - 100 mcg - Single bolus - GnRH stimulation test: blood drawn at baseline, 30, and 60 minutes for LH/FSH. Normal response: LH rises 3-6 fold.
- <strong>Subcutaneous (pulsatile pump)</strong> - 5-20 mcg per pulse - Every 60-120 minutes - Pulsatile administration via portable pump for fertility restoration. Mimics physiological GnRH secretion pattern.
Mechanism of Action
Gonadorelin activates the GnRH receptor on pituitary gonadotropes: 1. GnRH receptor binding: Binds to the GnRH receptor (GnRHR), a G-protein coupled receptor on anterior pituitary gonadotrope cells. 2. Gonadotropin release: Triggers release of stored LH and FSH through phospholipase C activation, calcium mobilization, and protein kinase C signaling. 3. Pulsatile physiology: In normal physiology, pulsatile GnRH release (every 60-120 minutes) is required to maintain gonadotropin secretion. Continuous exposure leads to receptor downregulation. 4. Downstream effects: LH stimulates testosterone production (Leydig cells) or ovulation; FSH stimulates spermatogenesis or follicular development.
Legal Status
Gonadorelin products Factrel and Lutrepulse previously held FDA approval, but the listed US products are discontinued. Drugs@FDA does not identify the discontinuations as resulting from a safety or effectiveness finding. Gonadorelin therefore has historical, not currently marketed, US approval.
Primary Sources
- Pulsatile GnRH therapy for hypothalamic amenorrhea. Journal of Clinical Endocrinology & Metabolism, 1993.
- GnRH stimulation test in the assessment of pubertal disorders. Arquivos Brasileiros de Endocrinologia & Metabologia, 2008.
Quick Answers
Where is the strongest evidence for Gonadorelin?
Gonadorelin has a well-established physiological and clinical evidence base, but its US approval is historical: Factrel and Lutrepulse are discontinued products. It remains a useful GnRH reference compound, while current availability and approved alternatives depend on jurisdiction and indication. Evidence context: HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research.
What are the main side effects of Gonadorelin?
Gonadorelin side effects and warning signals include Injection site reactions, Headache, Nausea, Flushing, and Ovarian hyperstimulation syndrome (with pulsatile therapy in women).
What evidence level is Gonadorelin?
Gonadorelin is rated Level A; the listed research status is Historical FDA Approval.